OncoMatch/Clinical Trials/NCT06933329
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
Is NCT06933329 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Zelenectide pevedotin for non-small cell lung cancer.
Treatment: Zelenectide pevedotin — This is a global, multicenter, open-label study that aims to assess the efficacy and safety of zelenectide pevedotin in participants with previously treated NECTIN4-amplified advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior line of systemic therapy in the advanced/metastatic setting (see inclusion criteria below). The study will comprise of 2 cohorts: Cohort A (non-squamous NSCLC) and Cohort B (squamous NSCLC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: NECTIN4 amplification
Confirmed NECTIN4 gene amplification by an analytically validated clinical trial assay
Allowed: EGFR actionable genomic alteration
Participants with known actionable genomic alterations (eg, EGFR, ALK, BRAF, MET, ROS1, NTRK1/2/3, RET, etc.) are eligible provided they have received or are not candidates for available standard targeted therapy
Allowed: ALK actionable genomic alteration
Participants with known actionable genomic alterations (eg, EGFR, ALK, BRAF, MET, ROS1, NTRK1/2/3, RET, etc.) are eligible provided they have received or are not candidates for available standard targeted therapy
Allowed: BRAF actionable genomic alteration
Participants with known actionable genomic alterations (eg, EGFR, ALK, BRAF, MET, ROS1, NTRK1/2/3, RET, etc.) are eligible provided they have received or are not candidates for available standard targeted therapy
Allowed: MET actionable genomic alteration
Participants with known actionable genomic alterations (eg, EGFR, ALK, BRAF, MET, ROS1, NTRK1/2/3, RET, etc.) are eligible provided they have received or are not candidates for available standard targeted therapy
Allowed: ROS1 actionable genomic alteration
Participants with known actionable genomic alterations (eg, EGFR, ALK, BRAF, MET, ROS1, NTRK1/2/3, RET, etc.) are eligible provided they have received or are not candidates for available standard targeted therapy
Allowed: NTRK1 actionable genomic alteration
Participants with known actionable genomic alterations (eg, EGFR, ALK, BRAF, MET, ROS1, NTRK1/2/3, RET, etc.) are eligible provided they have received or are not candidates for available standard targeted therapy
Allowed: NTRK2 actionable genomic alteration
Participants with known actionable genomic alterations (eg, EGFR, ALK, BRAF, MET, ROS1, NTRK1/2/3, RET, etc.) are eligible provided they have received or are not candidates for available standard targeted therapy
Allowed: NTRK3 actionable genomic alteration
Participants with known actionable genomic alterations (eg, EGFR, ALK, BRAF, MET, ROS1, NTRK1/2/3, RET, etc.) are eligible provided they have received or are not candidates for available standard targeted therapy
Allowed: RET actionable genomic alteration
Participants with known actionable genomic alterations (eg, EGFR, ALK, BRAF, MET, ROS1, NTRK1/2/3, RET, etc.) are eligible provided they have received or are not candidates for available standard targeted therapy
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy — advanced/metastatic
Participants must have received at least 1 prior line of systemic therapy in the advanced/metastatic setting
Must have received: platinum-based chemotherapy — advanced/metastatic
Participants with no known actionable genomic alterations must have received both platinum based therapy and immunotherapy given either sequentially or in combination for advanced/metastatic NSCLC
Must have received: immunotherapy — advanced/metastatic
Participants with no known actionable genomic alterations must have received both platinum based therapy and immunotherapy given either sequentially or in combination for advanced/metastatic NSCLC
Must have received: targeted therapy — advanced/metastatic
Participants with known actionable genomic alterations...are eligible provided they have received or are not candidates for available standard targeted therapy in the advanced/metastatic setting
Cannot have received: monomethyl auristatin E (MMAE) (vedotin) based therapy
Prior treatment with monomethyl auristatin E (MMAE) (vedotin) based therapy
Cannot have received: systemic anticancer therapy
Prior treatment with any systemic anticancer therapy within 28 days or 5 half-lives, whichever is shorter, prior to first dose of study treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Alaska Oncology and Hematology, LLC · Anchorage, Alaska
- University of California, Davis Comprehensive Cancer Center · Sacramento, California
- Massachusetts General Hospital · Boston, Massachusetts
- Dana Farber Cancer Institute · Boston, Massachusetts
- St. Vincent Regional Hospital - Cancer Centers of Montana · Billings, Montana
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify